Skip to main content

Table 6 Univariate and multivariate analysis of clinicopathologic factors for DFS

From: Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study

Variables

Univariate

Multivariate

HR

95% CI

P

HR

95% CI

P

Age (years)

 < 60 yr

1.000

     

 ≥ 60 yr

1.297

0.955–1.760

0.096

  

0.301

Sex

 Male

1.000

     

 Female

1.208

0.873–1.671

0.254

   

BMI

 < 23

1.000

     

 ≥ 23

0.970

0.714–1.318

0.847

   

Surgical approach

 Traditional open

1.000

     

 Laparoscopic-assisted

0.802

0.576–1.116

0.191

  

0.264

Intraoperative blood loss

 ≤ 100 ml

1.000

  

1.000

  

 >100 ml

1.777

1.252–2.522

0.001

1.829

1.279–2.615

0.001

Postoperative complications

 Negative

1.000

     

 Positive

1.365

0.892–2.090

0.151

  

0.838

Tumor length/diameter

 < 5 cm

1.000

     

 ≥ 5 cm

1.929

1.421–2.619

< 0.001

  

0.053

Histological type

 HD/MD/M-LD

1.000

     

 LD/MA/SRC

1.506

1.108–2.047

0.009

  

0.129

Vascular tumor embolus

 Negative

1.000

     

 Positive

1.779

1.285–2.464

0.001

  

0.901

Depth of Invasion (T)

 T1/T2/T3

1.000

     

 T4a/T4b

2.149

1.572–2.939

< 0.001

  

0.207

Lymph node metastasis (N)

 N0/N1

1.000

     

 N2/N3

2.650

1.897–3.701

< 0.001

  

0.690

TNM

  

< 0.001

  

< 0.001

 IIA

      

 IIB

2.748

1.380–5.469

0.004

2.634

1.323–5.246

0.006

 IIIA

3.216

1.715–6.033

< 0.001

3.347

1.783–6.281

< 0.001

 IIIB

6.268

3.340–11.762

< 0.001

6.941

3.687–13.065

< 0.001

 IIIC

12.823

6.476–25.392

< 0.001

13.420

6.751–26.677

< 0.001

Serum CEA level

 ≤ 5 ng/ml

1.000

     

 >5 ng/ml

1.022

0.701–1.490

0.911

   

Serum CA199 level

 ≤ 37 U/ml

1.000

     

 >37 U/ml

1.291

1.057–1.578

0.012

  

0.840

Adjuvant chemotherapy cycles

  

0.002

  

< 0.001

 Not received (A)

1.000

  

1.000

  

 7–8 or 10–12 cycles (B)

0.549

0.369–0.817

0.003

0.424

0.283–0.635

< 0.001

 4–6 or 6–9 cycles (C)

0.592

0.381–0.918

0.019

0.522

0.335–0.815

0.004

 ≤ 3 or 5 cycles (D)

1.058

0.664–1.687

0.812

0.836

0.519–1.349

0.464

  1. Note: HD/MD/M-LD High/Median/Median-Low differentiation adenocarcinoma, LD/MA/SRC Low differentiation adenocarcinoma/Mucinous adeno-carcinoma/ Signet-ring cell carcinoma, HR Hazard ratio, CI Confidence interval. P < 0.05, statistically significant